Irene Becklund Sells 7,573 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 7,573 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $30.25, for a total transaction of $229,083.25. Following the transaction, the insider directly owned 11,280 shares of the company’s stock, valued at approximately $341,220. This trade represents a 40.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Irene Becklund also recently made the following trade(s):

• On Wednesday, June 17th, Irene Becklund sold 4,490 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.50, for a total value of $141,435.00.

Hims & Hers Health Trading Up 11.1%

Shares of NYSE:HIMS opened at $35.44 on Friday. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The business has a 50 day moving average of $26.42 and a two-hundred day moving average of $26.58. The company has a market capitalization of $8.20 billion, a PE ratio of -393.79, a PEG ratio of 45.59 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.20 EPS. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.05 EPS for the current year.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Barclays raised its price target on Hims & Hers and maintained a bullish stance, reinforcing optimism around accelerating growth and margin improvement tied to the Novo Nordisk partnership. Hims & Hers Stock Jumps After Barclays Raises Price Target
• Positive Sentiment: Analysts and commentators see the company as a potential beneficiary of the peptide/GLP-1 market and an upcoming FDA review, which may provide a new catalyst for future growth. HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
• Positive Sentiment: Bullish coverage argues that international expansion and the renewed partnership with Novo Nordisk support Hims & Hers’ long-term revenue and EBITDA targets. Hims & Hers: The Bull Case Remains Strong
• Neutral Sentiment: Insider selling by Irene Becklund and COO Michael Chi was disclosed, but both transactions were tied to pre-arranged 10b5-1 plans and equity-award tax withholding, which makes the signal less concerning for investors. SEC filing for Michael Chi sale
• Negative Sentiment: Recent commentary still points to weak prior-quarter fundamentals, including modest revenue growth, declining margins, and a net loss, reminding investors that execution risk remains. Hims & Hers: The Bull Case Remains Strong

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Weiss Ratings lowered Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Truist Financial upped their price target on Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, May 22nd. BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Finally, Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $29.37.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC increased its stake in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares in the last quarter. BIT Capital GmbH lifted its position in shares of Hims & Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after acquiring an additional 938,728 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Hims & Hers Health by 25.6% in the fourth quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock valued at $12,064,000 after acquiring an additional 75,679 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares in the last quarter. Finally, CI Investments Inc. boosted its stake in shares of Hims & Hers Health by 6,659.7% in the third quarter. CI Investments Inc. now owns 206,510 shares of the company’s stock worth $11,713,000 after acquiring an additional 203,455 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.